McDermott DF, Lee J-L, Szczylik C, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 36, 2018 (suppl; abstr 4500).
Huidtoxiciteit zelden reden voor stoppen immuuntherapie bij kanker
sep 2020 | Immuuntherapie